Consonance-Hfw Acq Corp (SRZN)

$11.00 +1.00 (10.00%)
Market Cap 94.19M
Revenue (ttm) 10.66M
Net Income (ttm) -63.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -596.25%
Debt to Equity Ratio 0.00
Volume 45,100
Avg Vol 15,170
Day's Range N/A - N/A
Shares Out 8.56M
Stochastic %K 85%
Beta 0.60
Analysts Strong Sell
Price Target $38.50

Company Profile

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat di...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 489 9000
Address:
171 Oyster Point Boulevard, Suite 400, South San Francisco, United States
Phaaisatroll
Phaaisatroll Aug. 3 at 1:29 PM
$SRZN so Boehringer Ingelheim and Regeneron both acquired drug delivery technology that could reduce the dosing frequency of drugs for eye diseases. I can only see 1 other drug on Regeneron's ophthalmology pipeline. And their Eylea franchise is not growing anymore. They need new drugs. https://www.fiercebiotech.com/biotech/regeneron-acquires-uk-biotech-adding-oxulars-eye-disease-delivery-tech-portfolio
0 · Reply
Phaaisatroll
Phaaisatroll Aug. 2 at 11:58 AM
$SRZN will they use the early termination option or not?
0 · Reply
raticals
raticals Aug. 2 at 12:18 AM
$SRZN I’ll take it this week
1 · Reply
kshonstocks
kshonstocks Aug. 1 at 6:51 PM
200 dma b/o $SRZN good chart spot
0 · Reply
raticals
raticals Aug. 1 at 6:35 PM
$SRZN 😳
0 · Reply
Jw242
Jw242 Aug. 1 at 6:09 PM
$SRZN bout to slap the ask 🤷
0 · Reply
Phaaisatroll
Phaaisatroll Aug. 1 at 4:20 PM
$SRZN seems like Boehringer Ingelheim's license deal for the ophthalmology drug delivery technology also helps us. At least the share price moves up.
1 · Reply
raticals
raticals Jul. 31 at 7:58 PM
$SRZN 👀
0 · Reply
Phaaisatroll
Phaaisatroll Jul. 29 at 5:42 PM
$SRZN this is the standard of care right now. A lot of injections into the eye with Regeneron's Eylea(VEGF inhibitor).
1 · Reply
Phaaisatroll
Phaaisatroll Jul. 29 at 5:38 PM
$SRZN opinion somebody posted on LinkedIn regarding Boehringer Ingelheim's deal.
1 · Reply
Latest News on SRZN
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 14, 2025, 8:30 AM EDT - 2 months ago

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025, 4:05 PM EDT - 3 months ago

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 31, 2025, 4:05 PM EDT - 4 months ago

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Mar 24, 2025, 9:00 AM EDT - 4 months ago

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Surrozen to Present at Upcoming Healthcare Investor Conferences

Nov 6, 2024, 4:30 PM EST - 9 months ago

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Nov 6, 2024, 9:00 AM EST - 9 months ago

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Nov 4, 2024, 8:30 AM EST - 9 months ago

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Sep 24, 2024, 8:30 AM EDT - 11 months ago

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Jun 12, 2024, 8:30 AM EDT - 1 year ago

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 9, 2024, 8:30 AM EDT - 1 year ago

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Provides First Quarter 2024 Financial Results and Business Update

May 8, 2024, 4:05 PM EDT - 1 year ago

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Apr 3, 2024, 8:40 AM EDT - 1 year ago

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Apr 1, 2024, 8:30 AM EDT - 1 year ago

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Apr 1, 2024, 8:30 AM EDT - 1 year ago

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Surrozen Provides Corporate Update on Clinical Programs

Jan 18, 2024, 8:30 AM EST - 1 year ago

Surrozen Provides Corporate Update on Clinical Programs

Surrozen Provides Third Quarter 2023 Financial Results

Nov 8, 2023, 4:05 PM EST - 1 year ago

Surrozen Provides Third Quarter 2023 Financial Results

Surrozen Provides Second Quarter 2023 Financial Results

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Surrozen Provides Second Quarter 2023 Financial Results

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

Jun 5, 2023, 8:30 AM EDT - 2 years ago

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

May 10, 2023, 4:05 PM EDT - 2 years ago

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Apr 5, 2023, 8:30 AM EDT - 2 years ago

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript

Mar 25, 2023, 10:02 AM EDT - 2 years ago

Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Mar 22, 2023, 4:01 PM EDT - 2 years ago

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Mar 20, 2023, 4:30 PM EDT - 2 years ago

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 4, 2023, 4:41 PM EST - 2 years ago

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 14, 2022, 4:30 PM EST - 2 years ago

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Oct 10, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Surrozen Reports Second Quarter 2022 Financial Results

Aug 11, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports Second Quarter 2022 Financial Results

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Jun 13, 2022, 8:00 AM EDT - 3 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

May 24, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

May 18, 2022, 8:00 AM EDT - 3 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

May 16, 2022, 8:00 AM EDT - 3 years ago

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

Surrozen Reports First Quarter 2022 Financial Results

May 11, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports First Quarter 2022 Financial Results

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

May 5, 2022, 8:00 AM EDT - 3 years ago

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 2, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 24, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Jan 10, 2022, 8:00 AM EST - 3 years ago

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Jan 5, 2022, 8:00 AM EST - 3 years ago

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Surrozen Reports Third Quarter 2021 Financial Results

Nov 15, 2021, 4:00 PM EST - 4 years ago

Surrozen Reports Third Quarter 2021 Financial Results

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

Nov 15, 2021, 8:00 AM EST - 4 years ago

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Nov 15, 2021, 8:00 AM EST - 4 years ago

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

Nov 5, 2021, 8:00 AM EDT - 4 years ago

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action

Oct 6, 2021, 7:17 AM EDT - 4 years ago

Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action

Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week

Oct 5, 2021, 4:30 PM EDT - 4 years ago

Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

Sep 23, 2021, 8:30 AM EDT - 4 years ago

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

Here's why Surrozen shares are up more than 50% on Tuesday

Sep 7, 2021, 2:05 PM EDT - 4 years ago

Here's why Surrozen shares are up more than 50% on Tuesday

Phaaisatroll
Phaaisatroll Aug. 3 at 1:29 PM
$SRZN so Boehringer Ingelheim and Regeneron both acquired drug delivery technology that could reduce the dosing frequency of drugs for eye diseases. I can only see 1 other drug on Regeneron's ophthalmology pipeline. And their Eylea franchise is not growing anymore. They need new drugs. https://www.fiercebiotech.com/biotech/regeneron-acquires-uk-biotech-adding-oxulars-eye-disease-delivery-tech-portfolio
0 · Reply
Phaaisatroll
Phaaisatroll Aug. 2 at 11:58 AM
$SRZN will they use the early termination option or not?
0 · Reply
raticals
raticals Aug. 2 at 12:18 AM
$SRZN I’ll take it this week
1 · Reply
kshonstocks
kshonstocks Aug. 1 at 6:51 PM
200 dma b/o $SRZN good chart spot
0 · Reply
raticals
raticals Aug. 1 at 6:35 PM
$SRZN 😳
0 · Reply
Jw242
Jw242 Aug. 1 at 6:09 PM
$SRZN bout to slap the ask 🤷
0 · Reply
Phaaisatroll
Phaaisatroll Aug. 1 at 4:20 PM
$SRZN seems like Boehringer Ingelheim's license deal for the ophthalmology drug delivery technology also helps us. At least the share price moves up.
1 · Reply
raticals
raticals Jul. 31 at 7:58 PM
$SRZN 👀
0 · Reply
Phaaisatroll
Phaaisatroll Jul. 29 at 5:42 PM
$SRZN this is the standard of care right now. A lot of injections into the eye with Regeneron's Eylea(VEGF inhibitor).
1 · Reply
Phaaisatroll
Phaaisatroll Jul. 29 at 5:38 PM
$SRZN opinion somebody posted on LinkedIn regarding Boehringer Ingelheim's deal.
1 · Reply
Phaaisatroll
Phaaisatroll Jul. 28 at 7:34 PM
$SRZN Boehringer Ingelheim makes a deal to get some drug delivery technology for their ophthalmology pipeline. https://www.fiercebiotech.com/biotech/boehringer-eyes-1b-deal-use-re-vanas-drug-delivery-tech-ophthalmic-pipeline
1 · Reply
JoshThe3rd
JoshThe3rd Jul. 26 at 10:14 PM
$SRZN
0 · Reply
phaa
phaa Jul. 25 at 3:29 AM
$SRZN I see phaaisatroll has found a new stock to spread B.S about. Do your due diligence this stock has lost 95% of it's value in 5 years.
0 · Reply
Phaaisatroll
Phaaisatroll Jul. 23 at 7:16 PM
$SRZN new head of clinical development with a lot of experience in ophthalmology.
1 · Reply
Jw242
Jw242 Jul. 21 at 8:01 PM
$SRZN the heck was the volume abound end of day
0 · Reply
Jw242
Jw242 Jul. 15 at 4:00 PM
$SRZN fk you. Blowing me up for 3+ years.
0 · Reply
Jw242
Jw242 Jul. 15 at 2:13 PM
$SRZN may be time to throw in the towel 🤷
0 · Reply
Phaaisatroll
Phaaisatroll Jul. 12 at 8:43 AM
$SRZN 2 Surrozen scientists were involved in this work: https://www.biorxiv.org/content/10.1101/2025.07.08.663293v1
0 · Reply
Quantumup
Quantumup Jul. 10 at 7:51 PM
Cantor reiterated $APLS Overweight/$39 after competitor $ALPMY reported preliminary IZERVAY™ figures. $OCUL $EYPT REGN $SRZN RHHBY William Blair reiterated $APLS at an Outperform rating after competitor $ALPMY hosted a business update call to provide a U.S. commercial update on Izervay. Both Seem to Question #s Cantor and William Blair said in their notes to investors:
2 · Reply
Jw242
Jw242 Jul. 8 at 8:02 PM
$SRZN kinda mental 😅
0 · Reply
Jw242
Jw242 Jun. 30 at 8:02 PM
$SRZN very odd with the volume past few days
0 · Reply
Phaaisatroll
Phaaisatroll Jun. 29 at 4:51 AM
$SRZN another event with involvement of Surrozen.
1 · Reply